Squarepoint Ops LLC Reduces Position in Immunome, Inc. (NASDAQ:IMNM)

Squarepoint Ops LLC lowered its position in Immunome, Inc. (NASDAQ:IMNM) by 43.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,914 shares of the company’s stock after selling 13,772 shares during the quarter. Squarepoint Ops LLC’s holdings in Immunome were worth $190,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Enavate Sciences GP LLC purchased a new stake in Immunome during the 4th quarter valued at approximately $36,939,000. JPMorgan Chase & Co. increased its stake in Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock valued at $6,888,000 after buying an additional 624,045 shares during the period. Granahan Investment Management LLC acquired a new position in Immunome in the 4th quarter valued at $3,337,000. Renaissance Technologies LLC raised its position in Immunome by 2,696.5% during the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock worth $3,356,000 after buying an additional 304,700 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in Immunome by 127.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company’s stock worth $5,310,000 after buying an additional 280,000 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Trading Up 0.1%

IMNM stock opened at $9.13 on Monday. The firm has a 50 day moving average of $7.88 and a 200-day moving average of $9.50. The company has a market cap of $794.42 million, a price-to-earnings ratio of -1.13 and a beta of 1.94. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.81.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14. The firm had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $0.46 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. Sell-side analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on IMNM shares. Lake Street Capital assumed coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 target price on the stock. Lifesci Capital assumed coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective on the stock. Guggenheim dropped their target price on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Wedbush reissued an “outperform” rating and issued a $21.00 price target (down from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Finally, Stephens reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.33.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall bought 137,100 shares of the stock in a transaction on Wednesday, March 26th. The stock was purchased at an average cost of $7.29 per share, with a total value of $999,459.00. Following the purchase, the chief executive officer now owns 806,736 shares of the company’s stock, valued at approximately $5,881,105.44. The trade was a 20.47% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CTO Philip Tsai purchased 12,300 shares of Immunome stock in a transaction on Monday, March 24th. The shares were acquired at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the purchase, the chief technology officer now owns 33,300 shares in the company, valued at approximately $280,386. This trade represents a 58.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 161,400 shares of company stock valued at $1,207,395 in the last ninety days. Corporate insiders own 8.60% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.